Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck ProQuad / M-M-R II / Varivax by Quarter
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide reported growth YoY (%) (%)
Merck ProQuad / M-M-R II / Varivax: -3.0% in Q2 2026, down 2.0 pts from a year earlier.
Where the Q2 2026 figure comes from
“|| ProQuad/M-M-R II/Varivax | 592 | 609 | -3 | 438 | 481 | -9 | 154 | 128 | 20”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -3.0% | -2.0 pts | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 4.0% | -5.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | -3.0% | -2.0 pts | Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | -1.0% | -7.0 pts | Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗ |
| Q1 2025 | Mar 31, 2025 | -5.0% | -13.0 pts | Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗ |
| Q4 2024 | Dec 31, 2024 | 9.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | -1.0% | – | Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 6.0% | – | Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗ |
| Q1 2024 | Mar 31, 2024 | 8.0% | – | Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗ |
Cite this data
StockData. (2026). Merck ProQuad / M-M-R II / Varivax (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-proquad-mmr-varivax-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.